Related Articles
Clinical outcomes of anti-androgen withdrawal and subsequent alternative anti-androgen therapy for advanced prostate cancer following failure of initial maximum androgen blockade
Conversion to monotherapy with luteinizing‑hormone releasing hormone agonist or orchiectomy after reaching PSA nadir following maximal androgen blockade is able to prolong progression‑free survival in patients with metastatic prostate cancer: A propensity score matching analysis
Effect of dutasteride on castration‑resistant prostate cancer
Clinical outcome of oral uracil/tegafur (UFT) therapy for patients with hormone refractory prostate cancer
Neuroendocrine differentiation in castration-resistant prostate cancer: A case report